Investor Presentaiton slide image

Investor Presentaiton

ORIENT-11 (1L nsqNSCLC): Sintilimab Combination Achieved Significant Improvement in both PFS and OS Progression-free survival 1 PFS (by IRRC) Events HR (95% CI) P Sint+chemo 42.1% PL+chemo 65.6% 0.482 (0.362, 0.643) <0.00001 0.75- Sint+Chemo PL+Chemo 0.5 Sintilimab in combination with chemo demonstrated larger decrease of progression and death hazard as 1L therapy for non-squamous NSCLC Product Design PFS (by IRRC) ORIENT-11[1] Sintilimab Double-blind KEYNOTE-189[2] Pembrolizumab Double-blind NCT03663205[3] NCT03134872[4] Tislelizumab Open label Camrelizumab Open label 0.25- Median (95% CI), months 0 2 4 -10 6 8 10 12 14 16 Number at Risk Months HR (95% CI) Sint+Chemo 266 231 202 143 63 25 3 3 0 P 0.48 (0.36, 0.64) <0.00001 0.52 (0.43, 0.64) <0.001 8.9 (7.1, 11.3) vs 5.0 (4.8, 6.2) 8.8 (7.6, 9.2) vs 4.9 (4.7, 5.5) 9.7 (7.7, 11.5) vs 7.6 (5.6, 8.0) 11.3 (9.5, NR) vs 8.3 (6.0, 9.7) 0.61 (0.46, 0.80) 0.0002 0.65 (0.46, 0.90) 0.0044 PL+Chemo 131 106 77 42 19 4 1 0 0 OS Survival probaility 1 0.75 OS Sint+Chemo PL+Chemo # Median (95% CI), months HR (95%CI) P ESMO congress MHC-II antigen presentation pathway as a predictive biomarker for sintilimab plus chemotherapy as first-line treatment of non-squamous NSCLC Biomarker analysis of ORIENT-11 Study Yunpeng Yang M.D. Department of Medical Oncology, Sun Yat-sen University Cancer Center State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou, China NR vs NR 0.61 (0.40, 0.93) 0.01921 20 NR vs 11.3 (8.7, 15.1) Not reported 0.49 (0.38, 0.64) <0.001 2020 Presidential Symposium AUGUST 8, 2020 | WORLDWIDE ORIENT-11: sintilimab + pemetrexed + platinum as first-line therapy for locally advanced or metastatic non-squamous NSCLC Li Zhang, Yunpeng Yang, Zhehai Wang, Jian Fang, Qitao Yu, Baohui Han, Shundong Cang, Gongyan Chen, Xiaodong Me", Zhixiong Yang, Rui Ma, Minghong Bi, Xiubao Ren, Jianying Zhou, Baolan Li State Key Laboratory of Oncology in South China. Collaborative innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, China Shandong Cancer Hospital, China Peking University Cancer Hospital China: Tumor hospital of GuangZhuang Autonomous Region. China Shanghai Chest Hospital China: Hanan provincial people's hospital, China Hartin Medical University Cancer Hospital, China Anhui Provincial Hospital, China. "Affiliated Hospital of Guangdong Medical University Chine "Liaoning Cancer Hospital China The First Amiated Hospital of Bengbu Medical College China: Tian Cancer Institute & Hospital China The First Amiated Hospital Zhejiang Universty China Beijing Chest Hospital Capital Medical University. China Journal of Oncology NR (17.1, NR) vs 20.9 (14.2, NR) 0.72 (0.52, 1.01) 0.0272 ORIGINAL ARTICLE ARTICLES IN PRESS Log in at IASLC Log in Claim Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer: a randomized, double-blind, phase 3 study (ORIENT-11) Yuripang Yang Zheha Wang Jan Fang Donglei Zhu Wen Zhang Li Zhang X + how at autho 4+ +#+| 0.5 Events 6-mo OS rate HR (95% CI) P VIRTUAL Sint+chemo 19.2% 89.6% 0.25 0.609 (0.400,0.926) 0.01921 PL+chemo 29.8% 80.4% Number at Risk T T T 0 2 4 6 8 10 12 14 16 Months 266 262 248 206 134 72 18 3 0 Sint+Chemo PL+Chemo 131 128 113 92 Innovent 52 61 33 8 1 0 Confidential Copyright©2021 Innovent Biologics [1] Zhang L, et al. WCLC 2020 [2] Gandhi L, et al. NEJM 2018. DOI: 10.1056/NEJMoa1801005 [3] Lu S, et al. ESMO 2020 [4] Zhou CC, et al. WCLC 2019 20 20
View entire presentation